BPG-0812 / BPGbio - LARVOL DELTA

BPGbio to Present Novel Drug Target for Huntington’s Disease and AI Discovered Biomarkers for Alzheimer’s Disease at Society for Neuroscience 2024 (Businesswire) - "In the first study...researchers showed that reduction of the E2 ubiquitin-conjugating enzyme, UBE2K/HIP2, leads to a loss of mutant Htt aggregates, which cause Huntington’s Disease. Researchers also demonstrated that treatment with the UBE2K discharge inhibitor, BPG-0812...slowed the discharge of ubiquitin from UBE2K...The second-first study...identified several novel liver and immune system protein biomarkers linked to cognitive decline. Notably, one biomarker can predict the time until cognitive decline in patients with Alzheimer’s Disease. These biomarkers were discovered through an analysis of plasma and buffy coat samples from participants in the Massachusetts Alzheimer Disease Research Center’s longitudinal study, in collaboration with Harvard Medical School."

Biomarker • Preclinical • CNS Disorders • Huntington's Disease